William D. Tap, MD, medical oncologist, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses developing treatment opportunities in soft tissue sarcomas.

Soft tissue sarcomas represent approximately 80 different diseases, so it is difficult to develop broad treatment approaches, Tap explains. However, the paradigm of soft tissue sarcoma is shifting as nuances within these rare diseases are being better understood. 

As such, unique treatment opportunities are being developed internationally for patients with soft tissue sarcomas, Tap says. Broad program project areas are researching drug development and translational medicine to inform how to optimally tailor therapy to individual patients, Tap concludes.

Videos

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.  



Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas 

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

The treatment of patients with sarcoma was significantly affected by the COVID-19 pandemic, says Tap. Questions that arose during the height of the pandemic included how to appropriately continue patient care, how patients with cancer are affected by COVID-19, how to safely and remotely manage patients with cancer, and how to continue clinical research safely, Tap explains. Additionally, investigators in the field of sarcoma are trying to understand how COVID-19 affects patients based on the different types of treatments they receive, including chemotherapies, alkylating agents, anthracyclines, and targeted therapies, Tap adds. 

Ultimately, these questions remain less understood in sarcoma compared with other more common tumor types, Tap says. The hope is that enough data will be available from patients with sarcoma to draw conclusions about how the COVID-19 pandemic affected this patient population, concludes Tap.

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.  



Dr. Tap on the Effects of the COVID-19 Pandemic on Sarcoma 

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses future research efforts in sarcoma.

​Understanding how current therapies can be further evaluated, as well as collaborating with musculoskeletal radiologists to determine new response parameters, will be important research efforts that could advance the sarcoma space, says Tap.

Additionally, working with health outcome researchers and patients to develop new patient-reported outcome​s for specific sarcoma subtypes could aid in understand​ing how different courses of therapy affect patients, ​says Tap.

Finally, solidifying strong connections with pharmaceutical ​companies and international sarcoma communities could help unify the field to implement more pivotal, randomized, phase 3 clinical trials, Tap concludes.

William D. Tap, MD, discusses future research efforts in sarcoma.

Dr. Tap on Future Research Efforts in Sarcoma

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the rise of precision medicine in sarcoma.

The treatment landscape of sarcoma is rapidly evolving with regard to advances in science, technology, and biology, says Tap.

For example, the explosion of immunotherapy options has been transformative across multiple tumor types, Tap explains. Other areas of significant cancer research include epigenetics, cellular signaling, and DNA damage response patterns. 

Sarcoma is a prime target to implement precision medicine, as the disease is associated with numerous genomic aberrations, Tap says. 

Moreover, the field is moving toward tailoring treatments to individual disease subtypes based on genomic and epigenetic abnormalities rather than treating all patients with sarcoma with the same one-size-fits-all approach, concludes Tap. 

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.  



Dr. Tap on the Rise of Precision Medicine in Sarcoma 

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the importance of ​community and academic collaboration in sarcoma.

The treatment of patients with sarcoma is complex, requiring nuanced treatment decisions and collaboration, Tap explains.

For example, liposarcoma consists of a number of different diseases that ​have intrasubtype heterogeneity that require different types of therapy​, says Tap.

As such, community oncologists ​should partner with academic centers ​when possible to optimize patient care, Tap concludes.

William D. Tap, MD, discusses the importance of ​community and academic collaboration in sarcoma.








Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the evolution of precision medicine in soft tissue sarcomas.

Soft tissue sarcoma represents a heterogeneous group of malignancies, says Tap. The last World Health Organization criteria to be published contained more than 100 different sarcoma subtypes. 

The field recognizes that these sarcoma subtypes are different diseases with different biologies, presentations, and clinical courses, according to Tap. However, in the past, many of these subtypes were grouped together when attempts were made to develop new treatment strategies, Tap says. There have been a lot of issues with clinical trials with regard to how they were been designed and conducted, with investigators questioning whether these factors impacted results yielded from this research, adds Tap. 

Within the past 5 years, several new agents have emerged in the sarcoma field, says Tap; these drugs have allowed patients to receive treatment based on their individualized disease subtype. A better understanding of the clinical course that patients with some of these rare subtypes of disease experience has also been developed, according to Tap. This has allowed for better clinical trial designs that are right for the disease and right for the individualized patient, concludes Tap.

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

Dr. Tap on the Evolution of Precision Medicine in Soft Tissue Sarcomas

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumab as a treatment for patients with soft tissue sarcoma.

Olaratumab is unique because it is a monoclonal antibody that specifically targets the platelet-derived growth factor receptor (PDGFR). Although it was thought that this therapy would require a cellular signaling process, researchers initially believed that the entire PDGFR cellular signaling had to be repressed.

However, olaratumab is highly specific to PDGFR-α. Because olaratumab is associated with a significant improvement in overall survival, researchers are beginning to rethink how it affects immune cells, stem cells, and the tumor microenvironment. Tap hopes that olaratumab will help researchers understand more of the biology of sarcoma.

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma. 


Dr. Tap on Olaratumab in Patients With Soft Tissue Sarcoma

	The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases. Nevertheless, despite a growing knowledge of the genetic alterations involved, the translation of these discoveries into therapeutic success has been limited and the treatment for the majority of patients still relies on conventional cytotoxic agents. In this review, we address the emerging therapeutic strategies aimed at specific molecular targets that could potentially change this panorama.

Sarcomas represent a diverse group of neoplasms of mesenchymal origin that correspond to approximately 1.5% of all malignancies in adults.

Genetic aberrations in sarcomas occur as either simple karyotypic abnormalities, such as chromosomal translocations, amplifications, and deletions, or complex/unbalanced karyotypic changes following accumulated nonspecific gains and losses. Chromosomal translocations resulting in gene fusions and subsequent transcriptional dysregulation account for the majority of the genetic hallmarks identified in sarcomas.

 In addition to the formation of chimeric transcription factors involving oncogenes, translocations may result in the activation of proteins with tyrosine kinase function or autocrine growth factors. Conversely, tumors without specific cytogenetic abnormalities are characterized by genome instability, which results in multiple and alternative genomic aberrations of unclear significance and a complex karyotype.

One of the major breakthroughs that emerged from a molecular-based approach is exemplified in gastrointestinal stromal tumors (GIST).

 Despite this initial enthusiasm, targeting molecular alterations has been less fruitful in other histologies, in which genetic alterations rarely act as driver mutations. In this review, we will focus on novel potential molecular targets in non-GIST sarcomas 

. PDGFR in Sarcomas Platelet-derived growth factor receptors (PDGFRs) are tyrosine-kinase receptors consisting of either α- or β-chains forming three possible receptors: PDGFR-αα, PDGFR-αβ, and PDGFR-ββ. The activation of PDGFR depends on the interaction with platelet-derived growth factor (PDGF) ligands in the extracellular domain, which include 5 different isoforms. After dimerization, each PDGFR partner phosphorylates tyrosine residues located on the cytosolic tails.

Across different subtypes of sarcomas, signaling through PDGF/PDGFR has been shown to promote progression through cell cycle and avoidance of apoptosis, and result in pro-angiogenic effects and modulation of the tumor stroma.

 Activation of PDGFR results in downstream signaling through multiple pathways involving phosphatidylinositol-3-kinase (PI3K), phospholipase-C gamma (PLCγ), Rous sarcoma oncogene (SRC) kinases and rat sarcoma oncogene (RAS)/mitogen-activated protein kinase (MAPK) proteins.

In normal cells, high expression of PDGFRβ is seen in fibroblasts, pericytes and smooth muscle, and PDGFRα in megakaryocytes, fibroblasts, myoblasts, pericytes, smooth muscle, and neurons.

In dermatofibrosarcoma protuberans (DFSP), inhibition of PDGFβ/PDGFRβ with tyrosine kinase inhibitors20-25 resulted in significant clinical activity, leading to approval of imatinib by the US Food and Drug Administration (FDA) for the treat ment of patients with advanced/metastatic disease. The molecular hallmark of DFSP is the recurrent translocation t(17;22) (q22;q13), that results in the fusion of the collagen type I alpha 1 (COL1A1) promoter to PDGF, leading to constitutive activation of this pathway.

In a pooled analysis including 24 patients treated with imatinib, objective response rate (ORR) was 46% and median time to tumor progression (mTTP) was 1.7 years.

In addition, the PDGF/PDGFR pathway has been associated with the pathogenesis of different sarcomas including rhabdomyosarcoma, Kaposi’s sarcoma, synovial sarcoma, chondrosarcoma, osteosarcoma, and Ewing family sarcoma. Elevated expression of PDGFβ and co-expression of PDGFβ and PDGFRα has been correlated with high histological grades and poor prognosis in sarcomas.

 Postulated mechanisms include the modulation of angiogenesis, regulation of stroma-derived fibroblasts and autocrine stimulation of cellular growth.

 Overexpression of mRNA for PDGFRα and PDGF has been documented in sarcoma, highlighting the relevance of this autocrine loop.

 In addition, preclinical data suggest that blocking PDGF/PDGFR results in a potentiation of response to chemotherapy.

Pazopanib, an oral, multi-targeted tyrosine kinase inhibitor also active against PDGFR, was shown to prolong progression-free survival (PFS) versus placebo in pretreated patients with advanced non-adipocytic soft tissue sarcomas (median PFS, 4.6 months vs 1.6 months; HR 0.31; 

 <.0001) in a phase lll trial, and is currently approved by the FDA.

There are ongoing studies focusing on more specific inhibition of PDGFRα. Olaratumab (IMC-3G3) is a recombinant IgG1-type monoclonal antibody that binds with high affinity to PDGFRα and prevents PDGF from binding to the receptor; olaratumab also blocks downstream signaling through Akt and mitogen-activated protein kinase (MAPK).

 A phase lb/ll study evaluating the efficacy of doxorubicin with or without olaratumab has recently completed accrual (NCT01185964), and results are pending; in addition, a drug interaction study to evaluate the effects of concurrent administration with doxorubicin is ongoing (NCT02326025).

Potential Targets for Inhibition: KDR, PTPRB, and PLCG1 in Angiosarcomas

Angiosarcomas (ASs) are malignancies of vascular origin associated with a significant risk of metastases and an poor prognosis.

 In addition to its vascular origin, plentiful evidence indicates the activation of pro-angiogenic pathways in the development of ASs, including overexpression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs).

 Bevacizumab, a recombinant monoclonal antibody targeting VEGF-A, was studied in a single arm, phase II trial in patients with tumors of vascular origin (AS, N=23; epithelioid hemangioendothelioma, N=7). Four objective responses occurred (2 patients with AS and 2 patients with epithelioid hemangioendothelioma), resulting in an ORR of 17% with 50% (N=15) achieving stable disease; median PFS was 12.4 weeks.

 In the recently presented ANGIOTAX-PLUS study, patients with AS were randomized to receive weekly paclitaxel with or without bevacizumab. There were no statistically significant differences in ORR (40% vs 50%), median PFS (6.8 months vs 6.9 months), or median OS (19.5 months vs 15.9 months) between treatment arms.

 Sorafenib, a multi-targeted tyrosine kinase inhibitor with anti-angiogenic properties, was investigated in a prospective study encompassing different histologies.

Among a subset of 37 evaluable ASs patients, ORR was 14% and median PFS was 3.8 months, with the majority of patients with AS having stable disease as best response.

 Similarly, sorafenib resulted in response rates of 0% and 14.6% and transient tumor control in phase ll trials reported by von Mehren et al and Ray-Coquard et al, respectively.

Recent studies applying whole genome, whole exome, and targeted sequencing techniques provided further insight into potential therapeutic targets in ASs. Using gene expression profiling, Antonescu et al showed upregulation of vascular-specific receptor tyrosine kinases, including kinase insert domain receptor (KDR) and tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE1) and FLT1. Of note, KDR gene mutations were associated with high expression of KDR protein and occurred in 10% of patients with ASs (all arising from the breast).

In an analysis of 26 primary and 29 secondary ASs, Styring et al demonstrated significant deregulation of 103 genes. Once again, secondary ASs showed a genetic signature distinct from primary ASs, with upregulation of MYC, KIT, and RET and downregulation of CDKN2C.

 reported at least 1 driver mutation in angiogenesis signaling genes in 15 of 39 ASs (38%), the most common being MYC. Of note, these driver mutations were not mutually exclusive.

 PTPRB truncating mutations were found in 26% (10 out of 39) of AS samples and exposure of PTPRB-silenced cell cultures to sunitinib or vatalanib resulted in suppression of angiogenesis. In addition, activating mutations of PLCG1, a signal transducer of tyrosine kinases involved in cell growth, signaling, and maintenance of membrane phospholipids, were documented in 9% of the cases.

In line with these observations, a retrospective series investigating the effects of sorafenib in cohorts limited to patients with RT-associated AS of the breast found MYC and FLT4 coamplification in 2 out of 3 patients with objective responses (in total, 9 patients were assessable for response; ORR = 33%).

In summary, although objective responses are limited to a subset of patients, tyrosine kinase inhibitors and agents targeting angiogenesis are active and able to induce disease stabilization in unselected AS patients, representing a reasonable alternative beyond conventional cytotoxic chemotherapy. Findings from molecularly-based studies provide conceptual models for further investigation of anti-angiogenic therapies in AS.

ALK in Inflammatory Myofibroblastic Tumors (IMTs)

Inflammatory myofibroblastic tumors (IMTs) are tumors composed of spindle cell proliferation mixed with a collagenous stroma in an inflammatory background of granulocytes, lymphocytes, and plasma cells.

 In almost 50% of the cases, IMT harbors chromosomal aberrations that result in rearrangements involving the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23 or increased copy numbers without rearrangement. The product of this genetic variation is a receptor tyrosine kinase (RTK) that is constitutively activated, leading to cell growth and tumorigenesis.

Crizotinib is an oral tyrosine kinase inhibitor targeting ALK, MET, and ROS1 that was initially approved for the treatment of patients with non-small cell lung cancer. Recently, Butrynski et al reported a partial response in a patient with ALK-rearranged IMT treated with crizotinib, suggesting that this agent might also be effective in treating patients with ALK-rearranged IMT.41 Given these promising results and based on a strong rationale, a phase II trial is ongoing (NCT01524926).

MDM2 and CDK4 in Well-Differentiated/ Dedifferentiated Liposarcoma

Liposarcomas are soft tissue sarcomas of adipocytic origin that comprise different histologic subtypes, including welldifferentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS).

WDLPS and DDLPS are marked by amplifications involving chromosome 12, which occur in more than 80% to 90% of the cases.

 These 12q gains result in co-amplification of cyclin-dependent kinase 4 (CDK4) and MDM2 oncogenes. Several agents targeting MDM2 and CDK4 are currently in development, although the success rate with inhibitors used as single agents has been limited.

CDK4 is a cyclin-dependent kinase that regulates the G1—S phase transition in the cell cycle and promotes tumorigenesis through inhibition of the retinoblastoma (Rb) protein family.

Following prolonged disease stabilization in patients with WDLPS/DDLPS in a phase I trial,

 our group reported the results of a phase II trial with the CDK4/6 inhibitor palbociclib (PD0332991), which demonstrated a PFS rate of 66% at 12 weeks. Among 29 evaluable patients with CDK4 amplification enrolled in the therapeutic cohort, the median PFS was 18 weeks.

 Palbociclib was recently approved by the FDA for the treatment of patients with breast cancer. LEE011, a distinct orally bioavailable CDK4/6 inhibitor, was also shown to be tolerable and able to induce long-lasting disease stabilizations in a phase I clinical trial including multiple solid tumors.

Stable disease sustained for more than 4 and 6 cycles occurred in 26% and 14% of the patients, respectively.

 Additional studies to better characterize the efficacy of LEE011 are ongoing (NCT01237236, NCT02187783, NCT02343172).

		Figure 1. Pathways for Targeted Therapy in Non-GIST Sarcomas

		(1) PDGF/PDGFR and downstream pathways MAPK, JAK/STAT and PIK3/Akt/mTOR; (2) Novel targets for inhibition of angiogenesis: KDR, FLT-1/4 tyrosine kinase receptors, PLCG1 signal transducer, and PTPRB phosphatase receptor; (3) ALK; (4) MDM2, and CDK4; (5) Microphthalmia family transcription factors MTF, TFE3, TFEB, and TFEC; (6) PIK3/Akt/mTOR pathway; (7) IDH family of enzymes.

The MDM2 gene encodes an E3 ubiquitin ligase that binds to tumor suppressor p53 and targets p53 for proteasomal degradation. Therefore, MDM2 amplification/overexpression leads to increased p53 inactivation and results in a pro-oncogenic effect. In a pilot study investigating the oral MDM2 inhibitor RO5045337 (also known as RG7112), both reactivation of the p53 pathway and decreased cell proliferation were demonstrated between pre- and posttreatment biopsies.

 Among 20 patients, there was 1 partial response and 14 patents achieved disease stabilization.

In another phase l dose escalation study that included a sarcoma extension cohort, RO5045337/RG7112 demonstrated manageable toxicities, biomarker activity, and objective responses in patients with liposarcomas.50 Nevertheless, the same drug in combination with doxorubicin (NCT01605526) resulted in high incidence of neutropenia and thrombocytopenia.

Additional agents targeting MDM2 are currently under clinical development. These include SAR405838, presently being investigated in early-phase clinical trials (NCT01636479, NCT01985191), and AMG-232, a MDM2 inhibitor derived from AM-8553 (NCT01723020, NCT02110355).

Microphthalmia Family Transcription Factors in Alveolar Soft Part Sarcomas and Clear Cell Sarcomas

The micropthalmia (MiT) family transcription factors includes MITF, TFE3, TFEB, and TFEC, which are involved in regulation of cell growth, differentiation, and survival. Dysregulation of MiT family members results in aberrant activation of multiple genes, including c-Met. This leads to oncogenesis in different cancer types and is thought to be particularly relevant in alveolar soft part sarcoma (ASPS) and clear cell sarcoma (CCS).

 The c-Met product is a receptor tyrosine kinase activated upon interation with hepatocyte growth fact (HGF) frequently expressed in mesenchymal cells and also linked to intracellular signaling through intracellular signaling MAPK and AKT pathways,

 providing a rationale for further study of MET and other TKI inhibitors in ASPS and CCS.

In ASPS, TFE is fused to the ASPL gene as a consequence of a typical unbalanced t(X;17)(p11;q25) translocation, resulting in the ASPL-TFE3 fusion protein. Although the function of ASPL needs to be further clarified, TFE3 acts as a transcription factor and the fusion transcripts lead to MET transcriptional upregulation through the c-Met gene.

Also an MiT-associated tumor, CCS expresses different cytogenetic abnormalities. Typically, EWSR1-ATF1 fusion results from the t(12;22)(q13;q12) translocation

; in a smaller subset of patients, t(2;22)(q34;q12) translocation produces a EWSR1-CREB1 fusion-gene.

 These abnormalities induce MITF and c-Met expression. In preclinical models, blockade of c-Met activity and HGF resulted in CCS cell growth arrest.

Disappointingly, a phase 2 study of the MET inhibitor tivatinib in MITF-associated tumors produced no objective responses in 27 ASPS patients. In the same trial, only one objective response occurred among 11 patients with CSS.

In both entities (ASPS and CSS), although responses were seen with multi-targeted tyrosine kinase inhibitors, the role of MET inhibitors remains to be further investigated and a clinical trial with cabozantinib is ongoing (NCT01755195).

The PI3K-Akt-mTOR Pathway in PEComas, Myxoid/ Round Cell Liposarcomas, and Angiosarcomas The phosphotidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) is a key pathway in the control of cell proliferation, survival, and angiogenesis. Several preclinical and translational studies have addressed the role of the PI3KAkt- mTOR pathway and investigated the mechanism of action of mTOR inhibitors; evidences of activation of this pathway have been well demonstrated in sarcomas.

Ridaforolimus showed some degree of activity in phase l/ll studies,

 but failed to demonstrate a survival benefit when used as a maintenance therapy in a randomized phase lll trial (

Different mTOR inhibitors, including temsirolimus, everolimus, and sirolimus, were also evaluated in small prospective trials.

Despite limited efficacy in unselected patients with sarcomas, a histology-driven approach could further clarify the role of mTOR inhibitors in the treatment of this group of malignancies. Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms that exhibit features of both smooth muscle and melanocytic origin

 and are often characterized by the presence of inactivating mutations in tuberous sclerosis complex (TSC) genes TSC1 and TSC2, which are upstream inhibitors of the mTOR complex 1 (mTORC1).

 Although data are limited due to the rarity of this disease, durable responses have been reported with sirolimus and everolimus. In a series of 5 patients with non-pulmonary PEComas treated with sirolimus or everolimus, 3 complete responses and 1 partial response occurred. Molecular studies identified TSC2 aberrations in 4 of these patients.

Barretina et al reported a relatively high prevalence of 

 mutations (18%) in patients with myxoid/round-cell liposarcomas.

 Similarly, Demicco et al showed that although activating 

mutations occurred in only 14% of the cases and more frequently in round cell than myxoid tumors (33% vs 3%; 

 activation were observed, including loss of PTEN and upregulation of IGF1R.

In angiosarcomas, activation of the PI3K/Akt/mTOR pathway occurs as a result of VEGF downstream signaling, involving mTORC1, mTORC2, and phosphorylation of p70 S6-kinase (S6K). In preclinical models, the growth of AS cell lines was supressed by celecoxib and rapamycin,

 and inhibition of mTORC1, mTORC2, and phosphorylation of Akt was demonstrated. 

In addition to conventional mTOR inhibitors, there has been growing interest in the investigation of dual PI3K-mTOR inhibitors in these diseases, including BEZ235 (NCT01690871), VS5584 (NCT01991938) and DS7423 (NCT01364844).

The isocitrate dehydrogenase protein (IDH) family comprises of 3 enzymes, IDH1, IDH2, and IDH3, which show different intracellular spatial distributions. These isoenzymes are involved in the oxidative decarboxylation of isocitrate. Mutations in genes encoding IDH1 and IDH2 result in proteins with aberrant enzymatic activity that produce (D)-2-hydroxyglutarate (2HG). Cells with mutant IDH1 and IDH2 show accumulation of 2HG and subsequent epigenetic modifications involved in tumorigenesis.

 Initially identified in gliomas, IDH mutations are present in up to 50% to 60% of chondrosarcomas.

 Preclinical data suggest that differentiation of mesenchymal progenitor cells can be disrupted by transfection with IDH2 mutant constructs in mice, and that exposure to the demethylating agent 5-azacytidine was able to restore a differentiated phenotype.

 Both IDH1 (AG120) and IDH2 (AG221) inhibitors are currently under development for patients with different malignancies associated with IDH mutations, including gliomas and chondrosarcomas.

While conventional cytotoxic chemotherapy remains the predominant treatment modality for patients with advanced sarcomas, genomics may continue to pave the way for the development of personalized care. Despite evidence supporting a mechanistic rationale in different types of sarcomas, targeting these molecular aberrations translated into meaningful therapeutic and clinical benefits only in a small subset of scenarios and the use of wide molecular analyses remains investigational and limited to select clinical trials. Nevertheless, some of these discoveries begin to shape the treatment decisions in specific histologies, as exemplified by the use of mTOR inhibitors in PEComa, imatinib in DFSP, pazopanib in pre-treated, non-adipocytic sarcomas, agents targeting angiogenesis in vascular sarcomas and, potentially MDM2 and CDK4 inhibitors in liposarcomas.

Further exploration of novel targets in sarcomas demands the development of adequate cell lines and preclinical models, as well as practical tools for the selection of patients for early phase clinical trials, in order to potentiate the benefit of tailored approaches.

Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (RRM, WDP, SPD). Weill Cornell Medical College, Department of Medicine (WDP, SPD).

: Sandra P. D’Angelo, MD, Assistant Attending - Sarcoma Medical Oncology Service, 300 E 66th St, New York, NY 10065; phone: 646-888-4159; fax: 646-888-4252. E-mail: dangelos@mskcc.org.

			Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. 

			Wibmer C, Leithner A, Zielonke N, et al. Increasing incidence rates of soft tissue sarcomas? a population-based epidemiologic study and literature review. 

			Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. 

			Fletcher C DM, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone. Fourth Edition. WHO 2013;IARC WHO Classification of Tumours, No 5. ISBN-13 9789283224341

			Taylor BS, Barretina J, Maki RG, et al. Advances in sarcoma genomics and new therapeutic targets. 

			Frith AE, Hirbe AC, Van Tine BA. Novel pathways and molecular targets for the treatment of sarcoma. 

			Jain S, Xu R, Prieto VG, et al. Molecular classification of soft tissue sarcomas and its clinical applications. 

			Miettinen M, Lasota J . Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. 

			Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. 

			Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. 

			Tap WE, Schwartz GK. That’s the “GIST” of it: use of adjuvant imatinib after resection of a primary GI stromal tumor. J Clin Oncol. 2014;32: 1543—1546.

			Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. 

			Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. 

			Östman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. 

			Pietras K, Rubin K, Sjöblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. 

			Shah GD, Loizos N, Youssoufian H. et al. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer. 2010;116(4 suppl):1018-1026.

			Wang J, Coltrera MD, Gown AM et al. Cell proliferation in human soft tissue tumors correlates with platelet- derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. 

			Kilvaer TK, Valkov A, Sorbye SW, et al. Platelet-derived growth factors in non-GIST soft-tissue sarcomas identify a subgroup of patients with wide resection margins and poor disease-specific survival. 

			Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. 

			Simon MP, Pedeutour F, Sirvent N et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. 

			McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofÄ±brosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. 

			Kamar FG, Kairouz VF, Sabri AN. Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res. 2013;3:5.

			Ong HS, Ji T, Wang LZ, Yu ZW et al. Dermatofibrosarcoma protuberans on the right neck with superior vena cava syndrome: case report and literature review.

			Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. 

			Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. 

			van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. 

			Penel N, Italiano A, Ray-Coquard I, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. 

			Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. 

			Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

			Itakura E, Yamamoto H, Oda Y, et al. Detection and characterization of vascular endothelia growth factors and their receptors in a series of angiosarcoma. 

			Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. 

			Penel N, Blay JY, Mir O, et al. ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS). 

			Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. 

			Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). 

			von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. 

			Styring E, Seinen J, Dominguez-Valentin M et al. Key roles for MYC, KIT, and RET signaling in secondary angiosarcomas. 

			Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. 

			D’Angelo SP, Antonescu CR, Keohan ML, et al. Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.

			Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? 

			Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. 

			Butrynski JE, D’Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. 

			Pedeutour, F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. 

			Sirvent, N, Coindre JM, Maire G, et al. Detection of MDM2CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. A

			Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 

			Barretina J, Taylor BS, Banerji S, et al. Subtype-specifÄ±c genomic alterations defÄ±ne new targets for soft-tissue sarcoma therapy. 

			Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). 

			Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. 

Articles

The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.

Novel Molecular Targets for Drug Development in Non-GIST Sarcomas

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Soft tissue sarcomas are a rare and heterogeneous group of malignancies where there have not been tremendous advances, says Tap. In a randomized phase Ib/II study olaratumab, a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, was evaluated with or without doxorubicin. The results were significant, says Tap, with the combination showing a 10-month improvement in overall survival compared to doxorubicin alone in soft tissue sarcoma patients.

Based on these results, olaratumab received breakthrough designation status from the FDA and a large phase III study will now be conducted, says Tap.

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas 

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the idea of using combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

Tap says the rationale behind this study stems from research that showed that when GIST respond to imatinib, there is an important immune-mediated response that occurs. Research has also shown that an immune response is often responsible for the development of resistance to drugs such as imatinib. Tap says if a checkpoint inhibitor is given after a TKI, an improvement in the immune response is seen.

In this phase I study, dasatinib was combined with ipilimumab to treat patients with GIST and other sarcomas. Tap says the purpose of this study was to discover the correct dose. As drug resistance makes GIST difficult to treat, Tap is hoping that combining drugs such as dastinib and ipilimumab may be a new option for patients.

William D. Tap, MD